In clinical studies in which TYMLOS was administered once daily to postmenopausal women with osteoporosis: Early increases in a bone formation marker peaked
at month 11

P1NP* bone formation marker levels were maintained above baseline throughout treatment1

Bone turnover marker levels at peak and at end of study with TYMLOS1

P1NP and sCTX levels in clinical trial of TYMLOS

Serum procollagen type 1 N-propeptide.1

Serum collagen type 1 cross-linked C-telopeptide.1

See the abaloparatide
mechanism of action video

Reference: 1. TYMLOS™ [prescribing information]. Waltham, MA: Radius Health, Inc; 2017.

This site is intended for HCPs in the United States.

All other trademarks are the property of their respective owners.

© 2017 Radius Health, Inc.   All rights reserved.    12/17.   TYM-US-00847

This site is intended for HCPs in the United States.
TYMLOS is a trademark of Radius Health, Inc.
All other trademarks are the property of their respective owners.

© 2017 Radius Health, Inc.
All rights reserved. 12/17.
TYM-US-00847

Back to Top